Live Chat

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2024 Dec 20, 09:11

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Y Intercept Hong Kong Ltd

Vir Biotechnology Inc
Webhose 2024 Dec 16, 00:22

Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs By Investing.com

Vir Biotechnology Inc
Webhose 2024 Dec 12, 13:22

Vir Biotechnology's drugs receive FDA and EMA nods By Investing.com

Vir Biotechnology Inc
Webhose 2024 Dec 12, 08:12

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology Inc
Webhose 2024 Dec 11, 08:05

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.

Vir Biotechnology Inc
Webhose 2024 Dec 02, 21:50

Vir Biotechnology Trades Higher in Sympathy with Janux Therapeutics By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 29, 08:11

Victory Capital Management Inc. Acquires 15,696 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 26, 14:30

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs | Morningstar

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:30

Company Website: https://www.vir.bio SAN FRANCISCO -- (Bus

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:26

Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 24, 08:52

HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 24, 06:54

Head-To-Head Survey: Coherus BioSciences (NASDAQ:CHRS) vs. Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Inc

Latest news

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

Info

Spread

0.07

Spread (%)

0.9576 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

14:31 - 20:59

Tuesday

14:31-17:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1014996416

Shares Outstanding

137720000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.93

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments
Trustpilot
Live Chat